Cycloxygenase-2 inhibitors nonsteroid anti-inflammatory drugs: Current issues;Antiinflamatórios não esteróides inibidores da ciclooxigenase-2 (COX-2): Aspectos atuais

Revista Brasileira de Anestesiologia

Volumn 52, Issue 4, 2002, Pages 498-512

  Kummer, Carmen Luize ^a,b   Coelho, Tereza Cristina R B ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b HC da UFPE ^*  (Brazil)

Author keywords

Analgesics, Anti inflamatory: cycloxygenase 2 inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; ISOENZYME; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN;

ALZHEIMER DISEASE; CANCER; CARDIOVASCULAR SYSTEM; DRUG COST; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; ENZYME STRUCTURE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; NAUSEA; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; OVARY FUNCTION; PANCREAS FUNCTION; REVIEW; SIDE EFFECT; THROMBOCYTE FUNCTION;

EID: 0036328514     PISSN: 00347094     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Cyclooxigenase in biology and disease
2. Mixed messages modulation of inflammation and immune responses by prostaglandins and thromboxanes
3. New concepts in acute pain therapy: Preemptive analgesia
4. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
5. Non-opioid postoperative analgesia
6. 2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1
7. Controversies in the perioperative use of nonsteroidal antiinflamatory drugs
8. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nosteroidal anti-inflammatory drugs
9. Interpreting the clinical significance of the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2
10. Arachidonic acid oxygenation by COX-1 and COX-2
11. Nonsteroidal Anti-inflamatory drug prescribing: Past, present and future
12. The coxibs, selective inhibitor of cyclooxygenase-2
13. Physiological regulation of cyclooxygenase-2 in the kidney
14. Augmented expression of COX-2 in human atherosclerotic lesions
15. 2 and distal prostaglandin synthase-1
16. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
17. Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?
18. COX-1, COX-2, and COX-3 and the future of chronic inflammatory disease
19. Experimental models used to investigate the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
20. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specifec inhibitors
21. Rofecoxib [VIOXX. MK-0966.4-(4'methylsulfonylphenyl)-3-phenyl-2-(5H)furanone]: A potent and orally active cyclooxygenase-2 inhibitor-pharmacological and biochemical profiles
22. Efficacy of cyclooxygenase-2 specific inhibitors
23. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain
24. Parecoxib (parecoxib sodium)
25. Effects of nonsteroidal anti-inflammatory drugs on post-operative renal function in adults
26. Renal effects of cyclooxygenase 2 selective inhibitors
27. Cyclooxygenase inhibition decreases rennin content and lowers blood pressure in a model of renovascular hypertension
28. Inhibition of the rennin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa
29. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro
30. Dehydration activates an NF-kB-driven. COX-2 dependent survival mechanism in renal medullary intesticial cells
31. The renal medulla and hypertension
32. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2 inhibition
33. Cyclooxygenase-2 selective inhibitors impair glomerulogenesis and renal cortical development
34. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly
35. Acute tubulointersticial nephritis associated with the selective COX2 enzyme inhibitor, rofecoxib
36. Gastrointestinal toxic side effects of nonsteroidal antiiflammatory drugs and cyclooxygenase-2 specific inhibitors
37. Cyclooxygenase-2: A major therapeutic advance?
38. 2production
39. Cyclooxygenase-2 specific inhibitors - Are they safe?
40. Aspirin as an antiplatelet drug
41. Antiiniflammatory agents less dangerous for gastointestinal tract
42. New data on healing of nonsteroidal anti-inflammatory drug associated ulcers and erosion: Omeprazole NSAID steering committee
43. Cholestatic hepatitis in association with celecoxib
44. The hepatic safety and tolerability of the novel cyclooxygenase inhibitor celecoxib
45. Celecoxib-induced acute pancreatitis and hepatitis
46. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of "sulfa" allergy
47. Cyclooxygenase inhibition and thrombogenicity
48. Differences in the detection of cyclo-oxygenase 1 and 2 proteins in symptomatic and asymptomatic carotid plaques
49. Doubt and certainty about NSAID in the year 2000: A multidisciplinary expert statement
50. Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors
51. NSAIDS and COX-2 inhibitors: Competition between gastroprotection and cardioprotection
52. Nonsteroidal anti-inflammatory drugs and cognitive function: Have a beneficial or deleterious effect?
53. The control of labor
54. Use of a cycoloxygenase type-2 selective non-steroidal anti-inflammatory agent to preent preterm delivery
55. Neonatal end-stage renal failure associated with maternal ingestion of COX-2 selective inhibitor nimesulide as tocolytic
56. Extent, mode and dose dependence of anticancer effects
57. Proapoptotic anti-inflammatory drugs
58. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon
59. Effect of celecoxib on colorectal polyposis (FAP)